Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability

ClinicalTrials.gov ID: NCT00596453

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00596453. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Impact of Antibiotic Treatment on PSA Variability

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections. It has been suggested that antibiotic treatment influences PSA levels due to the fact that an increase in PSA levels may be caused by inflammation or swelling of the prostate. Antibiotics are used to treat such inflammatory conditions. However, it has not been proven that antibiotics can be used to lower PSA. This research is being done to see if treatment with the antibiotic Ciprofloxacin hydrochloride affects the Prostate-Specific Antigen (PSA) blood test. This study may also help doctors in deciding which patients need a prostate biopsy.

Study identification

NCT ID: NCT00596453
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 4
Lead sponsor: Johns Hopkins University; Other
Enrollment: 31 participants

Conditions and interventions

Conditions

Prostate Infections

Interventions

Ciprofloxacin hydrochloride Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 40 Years to 75 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2008 (Type not available)
Primary completion: Jun 2011 (Actual)
Completion: Jun 2011 (Actual)
Last update posted: Jan 23, 2017

2008 – 2011

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Johns Hopkins Hospital Outpatient Center	Baltimore	Maryland	21287	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00596453, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 23, 2017 · Synced Nov 14, 2026